Clinical Trial Update: Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (SATISFY-JP) evaluating satralizumab for pulmonary arterial hypertension is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Satralizumab (satralizumab)

Snippet

Sponsor: International University of Health and Welfare | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: ACTIVE_NOT_RECRUITING